Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

A diet high in saturated fat and cholesterol accelerates simian immunodeficiency virus disease progression.

Mansfield KG, Carville A, Wachtman L, Goldin BR, Yearley J, Li W, Woods M, Gualtieri L, Shannon R, Wanke C.

J Infect Dis. 2007 Oct 15;196(8):1202-10. Epub 2007 Sep 7.

2.

Contribution of peaks of virus load to simian immunodeficiency virus pathogenesis.

Regoes RR, Staprans SI, Feinberg MB, Bonhoeffer S.

J Virol. 2002 Mar;76(5):2573-8.

3.

Simian immunodeficiency virus encephalitis in rhesus macaques is associated with rapid disease progression.

Westmoreland SV, Halpern E, Lackner AA.

J Neurovirol. 1998 Jun;4(3):260-8.

PMID:
9639069
4.

Chronic binge ethanol consumption accelerates progression of simian immunodeficiency virus disease.

Bagby GJ, Zhang P, Purcell JE, Didier PJ, Nelson S.

Alcohol Clin Exp Res. 2006 Oct;30(10):1781-90.

PMID:
17010145
5.

Antigenic stimulation in the simian model of HIV infection yields dilated cardiomyopathy through effects of TNFalpha.

Yearley JH, Mansfield KG, Carville AA, Sokos GG, Xia D, Pearson CB, Shannon RP.

AIDS. 2008 Mar 12;22(5):585-94. doi: 10.1097/QAD.0b013e3282f57f61.

PMID:
18316999
6.

Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.

Engram JC, Dunham RM, Makedonas G, Vanderford TH, Sumpter B, Klatt NR, Ratcliffe SJ, Garg S, Paiardini M, McQuoid M, Altman JD, Staprans SI, Betts MR, Garber DA, Feinberg MB, Silvestri G.

J Immunol. 2009 Jul 1;183(1):706-17. doi: 10.4049/jimmunol.0803746.

7.

Decreased NK cell frequency and function is associated with increased risk of KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus macaques with high viral loads.

Bostik P, Kobkitjaroen J, Tang W, Villinger F, Pereira LE, Little DM, Stephenson ST, Bouzyk M, Ansari AA.

J Immunol. 2009 Mar 15;182(6):3638-49. doi: 10.4049/jimmunol.0803580.

8.

Correlation between SIV Tat evolution and AIDS progression in cerebrospinal fluid of morphine-dependent and control macaques infected with SIV and SHIV.

Noel RJ Jr, Marrero-Otero Z, Kumar R, Chompre-González GS, Verma AS, Kumar A.

Virology. 2006 Jun 5;349(2):440-52. Epub 2006 Apr 27.

10.

Acute-phase CD4+ T-cell proliferation and CD152 upregulation predict set-point virus replication in vaccinated simian-human immunodeficiency virus strain 89.6p-infected macaques.

Koopman G, Mortier D, Hofman S, Koutsoukos M, Bogers WM, Wahren B, Voss G, Heeney JL.

J Gen Virol. 2009 Apr;90(Pt 4):915-26. doi: 10.1099/vir.2008.006148-0. Epub 2009 Feb 17.

PMID:
19223489
11.

Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys.

Borsetti A, Baroncelli S, Maggiorella MT, Bellino S, Moretti S, Sernicola L, Belli R, Ridolfi B, Farcomeni S, Negri DR, Cafaro A, Ensoli B, Titti F.

Arch Virol. 2008;153(3):463-72. Epub 2007 Dec 15.

PMID:
18080858
12.

Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques.

Sauermann U, Siddiqui R, Suh YS, Platzer M, Leuchte N, Meyer H, Mätz-Rensing K, Stoiber H, Nürnberg P, Hunsmann G, Stahl-Hennig C, Krawczak M.

Genes Immun. 2008 Jan;9(1):69-80. Epub 2007 Dec 20.

PMID:
18094710
13.

Factors contributing to spontaneous Enterocytozoon bieneusi infection in simian immunodeficiency virus-infected macaques.

Singh I, Li W, Woods M, Carville A, Tzipori S.

J Med Primatol. 2006 Dec;35(6):352-60.

PMID:
17214663
14.

Differential CD4+ T-lymphocyte apoptosis and bystander T-cell activation in rhesus macaques and sooty mangabeys during acute simian immunodeficiency virus infection.

Meythaler M, Martinot A, Wang Z, Pryputniewicz S, Kasheta M, Ling B, Marx PA, O'Neil S, Kaur A.

J Virol. 2009 Jan;83(2):572-83. doi: 10.1128/JVI.01715-08. Epub 2008 Nov 5.

15.

Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine.

Wang Y, Blozis SA, Lederman M, Krieg A, Landay A, Miller CJ.

Clin Vaccine Immunol. 2009 Apr;16(4):499-505. doi: 10.1128/CVI.00471-08. Epub 2009 Feb 18.

16.

Tissue-specific reduction in DC-SIGN expression correlates with progression of pathogenic simian immunodeficiency virus infection.

Yearley JH, Kanagy S, Anderson DC, Dalecki K, Pauley DR, Suwyn C, Donahoe RM, McClure HM, O'Neil SP.

Dev Comp Immunol. 2008;32(12):1510-21. doi: 10.1016/j.dci.2008.06.006. Epub 2008 Jul 9.

PMID:
18606180
17.

Simian immunodeficiency virus types 1 and 2 (SIV mnd 1 and 2) have different pathogenic potentials in rhesus macaques upon experimental cross-species transmission.

Souquière S, Onanga R, Makuwa M, Pandrea I, Ngari P, Rouquet P, Bourry O, Kazanji M, Apetrei C, Simon F, Roques P.

J Gen Virol. 2009 Feb;90(Pt 2):488-99. doi: 10.1099/vir.0.005181-0.

PMID:
19141460
18.

Interleukin-18 predicts atherosclerosis progression in SIV-infected and uninfected rhesus monkeys (Macaca mulatta) on a high-fat/high-cholesterol diet.

Yearley JH, Xia D, Pearson CB, Carville A, Shannon RP, Mansfield KG.

Lab Invest. 2009 Jun;89(6):657-67. doi: 10.1038/labinvest.2009.29. Epub 2009 Apr 20.

19.

Viral and host correlates of serum resistin in simian AIDS.

Wachtman LM, Gualtieri L, Wanke C, Shannon R, Mansfield KG.

AIDS Res Hum Retroviruses. 2008 Jan;24(1):34-42. doi: 10.1089/aid.2007.0154.

PMID:
18275346
20.

Platelet decline: an early predictive hematologic marker of simian immunodeficiency virus central nervous system disease.

Wachtman LM, Tarwater PM, Queen SE, Adams RJ, Mankowski JL.

J Neurovirol. 2006 Feb;12(1):25-33.

PMID:
16595371
Items per page

Supplemental Content

Write to the Help Desk